Wed, April 10, 2013
Tue, April 9, 2013
[ Tue, Apr 09th 2013 ] - Market Wire
30 a.m. ET
Mon, April 8, 2013
Sat, April 6, 2013
Fri, April 5, 2013
Thu, April 4, 2013
Wed, April 3, 2013
Tue, April 2, 2013
Mon, April 1, 2013
Fri, March 29, 2013
Thu, March 28, 2013
Wed, March 27, 2013
Tue, March 26, 2013
Mon, March 25, 2013
[ Mon, Mar 25th 2013 ] - Market Wire
Health Canada Decision Appealed
Sun, March 24, 2013
Fri, March 22, 2013
Thu, March 21, 2013
Wed, March 20, 2013
[ Wed, Mar 20th 2013 ] - Market Wire
00am ET
Tue, March 19, 2013
Mon, March 18, 2013
Sun, March 17, 2013
Fri, March 15, 2013
Thu, March 14, 2013

Horizon Pharma to Present at the 20th Annual Future Leaders in the Biotech Industry Conference


//health-fitness.news-articles.net/content/2013/ .. -leaders-in-the-biotech-industry-conference.html
Published in Health and Fitness on Thursday, March 28th 2013 at 5:01 GMT by Market Wire   Print publication without navigation


March 28, 2013 07:30 ET

Horizon Pharma to Present at the 20th Annual Future Leaders in the Biotech Industry Conference

DEERFIELD, IL--(Marketwire - Mar 28, 2013) - Horizon Pharma, Inc. (NASDAQ: [ HZNP ]), today announced that Timothy P. Walbert, chairman, president and chief executive officer will present at the 20th Annual Future Leaders in the Biotech Industry Conference on Friday, April 5th at 1:30p.m. Eastern Time in New York, NY. Mr. Walbert will provide an overview of the Company and its corporate activities.

The presentation will be webcast live and may be accessed by visiting Horizon's website at [ http://ir.horizon-pharma.com ]. A replay of the webcast will be available for 10 business days.

About Horizon Pharma
Horizon Pharma, Inc. is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS/LODOTRA, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire, in-license and/or co-promote additional innovative medicines where it can execute a targeted commercial approach in specific therapeutic areas while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit [ www.horizonpharma.com ].



Publication Contributing Sources